Anti-Nanog 抗体

• ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-Nanog antibody (AB21624)

ab21624 at a 1/1000 dilution staining Nanog in human embryonic stem cells by ICC. An antibody towards Oct4, which has an identical staining pattern to ab21624, was used as a positive control.

• ICC/IF

AbReview53716****

Immunocytochemistry/ Immunofluorescence - Anti-Nanog antibody (AB21624)

Immunocytochemical analysis of Human iPSCs labeling Nanog with ab21624 at 1/75 dilution.

Image courtesy of Mick Wauchope

• WB

Unknown

Western blot - Anti-Nanog antibody (AB21624)

ab21624 recognizes human Nanog but does not recognize mouse Nanog in Western Blot.

All lanes:

Western blot - Anti-Nanog antibody (ab21624) at 1/1000 dilution

Lane 1:

whole cell extract of mouse 3T3 cells expressing mouse Nanog.

Lane 2:

whole cell extract of mouse 3T3 cells expressing human Nanog.

Predicted band size: 34 kDa

Observed band size: 38 kDa

false

• WB

Supplier Data

Western blot - Anti-Nanog antibody (AB21624)

All lanes:

Western blot - Anti-Nanog antibody (ab21624) at 1/200 dilution

Lane 1:

Human fetal fibroblast lysate

Lane 2:

Human iPS cell lysate

Predicted band size: 34 kDa

false

• sELISA

Unknown

Sandwich ELISA - Anti-Nanog antibody (AB21624)

Standard Curve for Nanog (Analyte : Nanog protein (ab50053)); dilution range 1 pg/ml to 1 ug/ml using Capture Antibody Mouse monoclonal [1E6C4] to Nanog (ab76586) at 0.2 ug/ml and Detector Antibody Rabbit polyclonal to Nanog - ChIP Grade (ab21624) at 0.5 ug/ml.

• ICC/IF

CiteAb

Immunocytochemistry/ Immunofluorescence - Anti-Nanog antibody (AB21624)

Immunocytochemistry-immunofluorescence using Anti-Nanog antibody, ab21624. Publication image from Li, W. et al., 2019, Nat Commun, 31350386. Legend direct from paper.

CRISPR/Cas9-mediated gene targeting of DGCR8 in hESCs. a Schematic diagram of DGCR8 targeting using CRISPR/Cas9-mediated genome editing with homologous recombination. Neo stands for neomycin-resistance gene cassette used for positive selection. Red triangle indicates the FRT site. b Western blotting analysis of DGCR8 with protein extracts from WT and DR8dex2 hESCs. β-actin was used as the loading control. c G-banded karyotyping analysis of WT and DR8dex2 hESCs. d Immunofluorescence analysis of pluripotency markers OCT4, SOX2, and NANOG in WT and DR8dex2 hESCs. Scale bar, 12.5 µm. e Immunofluorescence analysis of representative markers of three germ layers in teratomas derived from WT or DR8dex2 hESCs. Scale bar, 50 µm. f Clonal expansion analysis of WT and DR8dex2 hESCs. Data were presented as mean ± SEM. n = 3 wells per cell type, ns means no significance. g Cell cycle analysis of WT and DR8dex2 hESCs. n = 3 wells per cell type, ns means no significance. Statistical significances were assessed by a two-tailed unpaired Student’s t test

• ICC/IF

CiteAb

Immunocytochemistry/ Immunofluorescence - Anti-Nanog antibody (AB21624)

Immunocytochemistry-immunofluorescence using Anti-Nanog antibody, ab21624. Publication image from Kuo, H. C. et al., 2017, Nat Commun, 29074849. Legend direct from paper.

Disrupting circBIRC6 or circCORO1C impairs hESC pluripotency. a The schematic illustrates how circular junction sites were targeted for circRNA-specific shRNAs (shcircRNAs). The schematic also shows the targeted regions for RT-qPCR primers. Divergent primers were used for circRNAs and convergent primers for the linear isoforms. b–d Total RNA isolated from hESCs transfected with shcircB, shcircC, shcircMa, or paired control virus 3 days post transduction was analyzed by RT-qPCR to determine the expression levels of bcircBIRC6 (circB), circCORO1C (circC), circMAN1A2 (circMa), and their linear counterparts (LinB, LinC, and LinMa), and the indicated c pluripotency-associated genes and d lineage-associated genes. e AP staining of shcircB, shcircC, and shcircMa-transduced H9 hESCs. Scale bar : 200 µm. f ICC analysis of shcircB, shcircC, or shcircMa-transduced H9 hESCs 3 days post virus infection using antibodies against the pluripotency and lineage markers as indicated. The corresponding bar graphs show quantitative analysis of the percentage of cells expressing pluripotency-associated markers or lineage-associated markers. Scale bar : 20 µm. g ICC and quantitative comparison of NANOG and OCT4 expression between shcircB-transduced and shcircC-transduced hESCs and their counterparts rescued by overexpression of circBIRC6 (H9-shcircB-res) or circCORO1C (H9-shcircC-res). Nuclei were stained with DAPI (blue). Scale bar : 20 µm. h RT-qPCR analysis of the expression of the indicated pluripotency-associated genes in shcircB-transduced or shcircC-transduced H9 hESCs and their rescued counterparts, H9-shcircB-res and H9-shcircC-res. Quantitative data from three independent experiments is presented as mean ± SD (error bars). P-values were determined by two-tailed two-sample t-tests (*P < 0.05; **P < 0.01; ***P < 0.001)

• ICC/IF

CiteAb

Immunocytochemistry/ Immunofluorescence - Anti-Nanog antibody (AB21624)

Immunocytochemistry-immunofluorescence using Anti-Nanog antibody, ab21624. Publication image from Kuo, H. C. et al., 2017, Nat Commun, 29074849. Legend direct from paper.

CircBIRC6 or circCORO1C promote hESC pluripotency. a Schematic illustrating the major components of circRNA minigene constructs. Arrows indicate the placement and direction of RT-qPCR primers used to amplify circRNA or precursor transcripts. b–d RT-qPCR analysis of the expression of b circRNAs and their precursor transcripts, and the indicated c pluripotency-associated genes and d lineage-associated genes in hESCs transfected with a circRNA minigene (H9-circB, H9-circC, and H9-circMa) cultured under differentiation conditions. e ICC analysis and f quantitative analysis of the expression of the pluripotency and lineage markers as indicated in hESCs transfected with a circRNA minigene (H9-circB, H9-circC, and H9-circMa) and cultured under differentiation conditions. Nuclei were stained with DAPI (blue). Scale bar : 20 µm. Quantitative data from three independent experiments is presented as mean ± SD (error bars). P-values were determined by two-tailed two-sample t-tests (*P < 0.05; **P < 0.01; ***P < 0.001)

• WB

CiteAb

Western blot - Anti-Nanog antibody (AB21624)

Western Blotting using Anti-Nanog antibody, ab21624. Publication image from Ansorge, O. et al., 2016, Nat Commun, 26899176. Legend direct from paper.

Transformation of human iNPCs results in the acquisition of a GTIC-like phenotype in vitro.(a) Flow cytometry analysis for the indicated markers in different transformed and wild-type iNPC groups (n=4/group with technical duplicates). (b) Transformation of human iNPCs leads to increased self-renewal properties only in cells where PI3K and MAPK signalling is dysregulated by overexpression of Ras/EGFR/Src mutant genes as highlighted by single-cell self-renewal assays (n=3/group with 24 technical replicates). (c) iNPC transformation results in the upregulation of endogenous NANOG as highlighted by western blot analyses. (d) NANOG expression is upregulated in primary human adult glioma samples. (e) Unsupervised cluster analysis of mRNA expression data highlighting the similarities between transformed iNPCs and primary GTICs. Please note that p53KDiNPCs are more similar to WTiNPCs than to primary GTICs. (f,g) Transformation of human iNPCs induces glycolytic (f) and oxidative phosphorylation changes as indicated by Seahorse analysis (g), as measured by ECAR and OCR (n=4/group with four technical replicates). Data are represented as mean ±s.d. P values were calculated by Student's t-test or Mann–Whitney test when appropriate and represented as follows : *P<0.05. Scale bars, 200 µm (d).

false